Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

For most people, the word cancer implies that there’s a tumor or mass growing somewhere in the body. However, contrary to ...

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or ...

Positive preliminary outcomes were reported for the first leukemia patient treated with Ossium Health's organ donor bone ...

Hunter Tate has received news that he is officially in remission, moving from a high-risk to a low-risk protocol and no ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

“We a NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Secondary Acute Myeloid Leukemia.

Symptoms of blood cancer vary by disease type, and many blood cancers have no obvious symptoms in their earliest stages ... refractory anemia and acute myeloid leukemia (AML).

Exploring the triple combination with venetoclax and azacitidineStudy sponsored by Oregon Health & Science University (OHSU)MADRID and ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...